ArticleiScience2025
Cerenkov luminescence microscopy: A novel approach for high-resolution radiotracer imaging.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NIS-Centered Reporter Gene Imaging and Radionuclide-Integrated Nanoplatforms for Quantitative Tracking of Immune Cell Therapy in Oncology and Inflammatory Disease Models.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study introduces a novel imaging system utilizing Cerenkov luminescence microscopy (CLM) to visualize the activity of radioactive tracers in 3D tumor spheroids. The system integrates an EMCCD camera, a microscope objective, and a precise sample positioning setup, enabling the high-resolution detection of Cerenkov light emission from radiotracers in a light-tight environment. The characteristics of the new CLM system have been tested on glioblastoma multiforme (GLM) spheroids, subjected or not to X-ray radiotherapy. The system effectively differentiated irradiated from non-irradiated spheroids by detecting distinct variations in signal intensity, which were further validated through comparison with autoradiography and quantitative activity measurements. This demonstrates the system's ability to provide highly sensitive imaging of radiolabeled biological samples. The method offers new possibilities for studying radiopharmaceutical distribution and metabolic processes at the cellular level, making it a valuable tool for advancing both diagnostic and therapeutic radiopharmaceutical development, as well as for evaluating treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.